[PDF][PDF] Vandetanib versus gefitinib in patients with advanced non–small-cell lung cancer: results from a two-part, double-blind, randomized phase II study
RB Natale, D Bodkin, R Govindan… - Journal of Clinical …, 2009 - researchgate.net
RB Natale, D Bodkin, R Govindan, BG Sleckman, NA Rizvi, A Capó, P Germonpré…
Journal of Clinical Oncology, 2009•researchgate.netPurpose Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor
receptor (VEGFR) and epidermal growth factor receptor (EGFR) signaling. In this two-part
phase II study, the efficacy and safety of vandetanib was compared with that of gefitinib, an
inhibitor of EGFR signaling.
receptor (VEGFR) and epidermal growth factor receptor (EGFR) signaling. In this two-part
phase II study, the efficacy and safety of vandetanib was compared with that of gefitinib, an
inhibitor of EGFR signaling.
Purpose
Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) signaling. In this two-part phase II study, the efficacy and safety of vandetanib was compared with that of gefitinib, an inhibitor of EGFR signaling.
researchgate.net